NPPA Fixes Retail Prices for 41 Essential Drug Formulations
The National Pharmaceutical Pricing Authority (NPPA) has issued an order on June 3, 2025, fixing the retail prices for 41 specific drug formulations. The newly fixed retail prices are exclusive of Goods and Services Tax (GST) and are applicable to the formulations as specified by their strength, unit, and the respective manufacturer and marketing company. Manufacturers are permitted to add GST only if it has been actually paid or is payable to the Government.
NPPA Sets Retail Prices for 80 New Drugs
The National Pharmaceutical Pricing Authority (NPPA), under the Ministry of Chemicals and Fertilizers, has announced the fixation of retail prices for 80 new drug formulations, aiming to ensure affordability and accessibility for consumers.
Correction In Price Issued For Synchrobreathe Inhaler
The price of the Synchrobreathe Inhaler for Budesonide Inhalation (MDI) 200 mcg/dose for 200 doses has therefore been revised to correct a typographical error. It is now fixed at Rs. 81.20 pe.r inhaler
NPPA Fixes Retail Price for Cilnidipine & Telmisartan Tablets
Each film coated Cilnidipine & Telmisartan Tablet shall bear the retail price of Rs. 14.15. This price applies to tablets manufactured by M/s Akums Drugs & Pharmaceuticals Ltd. and marketed by M/s Glenmark Pharmaceuticals Limited.
NPPA Revises Ceiling Prices of Azithromycin & Amoxicillin + Clavulanic Acid
Manufacturers selling these formulations (branded or generic) above the revised ceiling price (plus applicable GST) must immediately revise their prices downwards to comply. Retailers and dealers must prominently display the price list provided by the manufacturer.
NPPA Fixes Retail Prices For 42 Formulations
The National Pharmaceutical Pricing Authority (NPPA) has fixed the retail prices for 42 pharmaceutical formulations. These prices are exclusive of Goods and Services Tax, if applicable. These prices were notified on February 7, 2025.
Drug Price Display Mandatory for Online and On-Site Pharmacies
Online pharmacies operating through websites, portals, mobile apps, e-commerce platforms, or any other online mode are equally obligated to display the current price list of drugs as brick-and-mortar stores.
India’s Drug Pricing Policy Focuses on Essentiality and Market-Based Mechanisms
The policy emphasizes several key principles, including regulating prices based on the essentiality of drugs, focusing price controls on consumer-level formulations (medicines) rather than bulk drugs or intermediates, and using market-based pricing mechanisms instead of cost-based pricing.
NPPA Approves Separate Pricing for Cipla’s Synchrobreathe Inhaler Device
The National Pharmaceutical Pricing Authority (NPPA) has approved separate pricing for Cipla Ltd.’s “Synchrobreathe Inhaler Device” when used with specific Budesonide and Formoterol formulations. This decision follows recommendations from a Multidisciplinary Committee of Experts and aims to promote incremental innovation in drug delivery.
NPPA Fixes Retail Prices For 65 Formulations
The National Pharmaceutical Pricing Authority (NPPA) has fixed the retail prices for 65 pharmaceutical formulations. The retail price for these specified formulations must match the specified price. Manufacturers are required to submit a price list in Form–V via IPDMS to the National Pharmaceutical Pricing Authority (NPPA) and provide copies to State Drug Controllers and dealers.
